Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-Obstructive Coronary Atherosclerosis Clear all
Recruiting Not applicable Interventional

Imaging Coronary Microvascular Dysfunction (CMD) Study

NCT05634031
View directory record Official record
Conditions
Angina, Non-obstructive Coronary Artery Disease
Interventions
PET imaging, Coronary CT angiogram, Functional Angiography, Treadmill exercise stress study
Radiation · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Jun 10, 2026, 8:16 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease

NCT00584896
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PB127 for Injectable Suspension
Drug
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Tucson, Arizona • Burlingame, California • Long Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Jun 10, 2026, 8:16 PM EDT
Terminated No phase listed Observational

PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease

NCT05031520
View directory record Official record
Conditions
Non-Obstructive Coronary Atherosclerosis
Interventions
Coronary computed tomography angiography (CCTA), Isovue, Nitroglycerin, Metoprolol
Procedure · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 125 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 10, 2026, 8:16 PM EDT
Completed No phase listed Observational

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

NCT00001534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions
Losartan
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 8:16 PM EDT
Completed No phase listed Observational

WARRIOR Ancillary Study for CCTA Analysis

NCT05035056
View directory record Official record
Conditions
Coronary Artery Disease, Non-Obstructive Coronary Atherosclerosis, Ischemia
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 10, 2026, 8:16 PM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

NCT06424834
View directory record Official record
Conditions
Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
Interventions
Amlodipine, Nebivolol, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jun 10, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional Results available

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

NCT04614467
View directory record Official record
Conditions
Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Microvascular Coronary Artery Disease
Interventions
CLBS16, Placebo
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Gainesville, Florida • Hollywood, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 10, 2026, 8:16 PM EDT
Recruiting Phase 1 Interventional

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

NCT06600178
View directory record Official record
Conditions
Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
Interventions
Brezavvy 20Mg Oral Tablet, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jun 10, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

NCT02147067
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Jun 10, 2026, 8:16 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
243
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 8:16 PM EDT
Active, not recruiting Phase 4 Interventional

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

NCT03417388
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2,476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
80
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 8:16 PM EDT
Active, not recruiting Phase 3 Interventional

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 8:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction

NCT05150054
View directory record Official record
Conditions
Coronary Microvascular Dysfunction, Ischemic Non-Obstructive Coronary Artery Disease
Interventions
CardioFlux
Device
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Detroit, Michigan • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Jun 10, 2026, 8:16 PM EDT
Recruiting No phase listed Observational

Evaluation of Patients With Non-obstructive Coronary Arteries

NCT00823563
View directory record Official record
Conditions
Chest Pain, Ischemia
Interventions
30 cc blood draw, Intravascular ultrasound (IVUS), Coronary pressure/flow wire testing, Coronary pressure/flow testing: Acetycholine challenge, Procedure: Coronary pressure/flow testing: Nitroglycerin challenge, Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2047
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 10, 2026, 8:16 PM EDT
Recruiting Not applicable Interventional

Analysis of Coronary Reactivity Testing With and Without Intracoronary Nitrate Testing

NCT06896903
View directory record Official record
Conditions
ANOCA - Angina With Non-obstructive Coronary Arteries, INOCA (Ischemia With Non Obstructive Coronary Artery Disease)
Interventions
Coronary reactivity testing with and without nitrates
Diagnostic Test
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 8:16 PM EDT
Not yet recruiting Not applicable Interventional

Inorganic Nitrate as a Treatment for ANOCA: NO-ANOCA

NCT06948201
View directory record Official record
Conditions
Coronary Microvascular Dysfunction (CMD), Angina Patients With Non-obstructive Coronary Artery Disease
Interventions
70mL Nitrate Rich Beetroot Juice followed by placebo (Nitrate depleted beetroot juice), Placebo (70 mL Nitrate depleted beetroot juice) followed by 70mL Nitrate Rich Beetroot Juice
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 10, 2026, 8:16 PM EDT
Recruiting Phase 1 Interventional

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

NCT05762952
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jun 10, 2026, 8:16 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease

NCT00595244
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PB127 for injectable suspension
Drug
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
15
States / cities
Phoenix, Arizona • Long Beach, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Jun 10, 2026, 8:16 PM EDT
Terminated Phase 1 Interventional

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

NCT05625347
View directory record Official record
Conditions
Obstructive Pulmonary Function, Restrictive Pulmonary Function
Interventions
single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Jun 10, 2026, 8:16 PM EDT